Image
home
James is now classed as an adult, which I find hard because developmentally he is not an adult and probably never will be.
James’ mother

CHANGING THEIR LIVES

by reducing seizure frequency in Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS)

 

The first and only regulatory-approved pharmaceutical CBD medicine in LGS and DS in Europe.1

 

Epidyolex is indicated for use as adjunctive therapy of seizures associated with LGS or DS, in conjunction with clobazam, for patients 2 years of age and older.1 Epidyolex has orphan designation for the treatment of LGS and DS.

 

Quality of life

Patients and caregivers of patients taking Epidyolex reported an improvement in overall condition on a Global Impression of Change scale compared to placebo.1

 

Image
quality_of_live_image
I almost lived in the hospital. I had my backpack ready at the door for when Miquel had a seizure in the hospital.
Miquel’s mother

Latest articles and events

Why prescribe Epidyolex?

Proven sustained efficacy
Demonstrated seizure reduction and is generally well tolerated in large Phase III clinical trials, across a range of ages.1

Large clinical development programme
GW Pharmaceuticals has conducted a large clinical trial programme within LGS and DS, including 714 patients.1

Image
UK pack _box only
Image
UK pack_bottle only

Novel Mechanism of Action
The novel Mechanism of Action provides a new approach to treating seizures.1 The precise mechanism by which Epidyolex exerts its anticonvulsant effects in humans is unknown.

More than 20 years of research
Developed following more than 20 years of cannabinoid research and development by GW Pharmaceuticals.

UK manufacturing

Industry-leading facilities and process at GW Pharmaceuticals

 

 

Image
video
Image
efficaci_img

Efficacy

Significant seizure reduction in controlled trials vs. placebo, which was sustained at 48 weeks in both LGS and DS1

 

Overall population is presented in-line with data provided in the Summary of Product Characteristics (SmPC). Epidyolex should only be prescribed as per the licensed indication. Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older.1

 

The recommended starting dose is 2.5 mg/kg twice daily. Based on individual clinical response and tolerability, if required this can increase in weekly increments of 2.5 mg/kg twice daily up to the maximum recommended dose of 20 mg/kg/day.1 Any dose increases above 10 mg/kg/day, up to the maximum recommended dose of 20 mg/kg/day, should be made considering individual benefit and risk and with adherence to the full monitoring schedule.1

Epidyolex is generally well tolerated

429 patients have been exposed to Epidyolex in Phase III controlled trials, as part of a large clinical trial programme within LGS and DS.1

 

Overall population is presented in-line with data provided in the SmPC. Epidyolex should only be prescribed as per the licensed indication.

 

Introducing Epidyolex in existing anti-epileptic drug (AED) regimens

 

Epidyolex can interact with some commonly prescribed AEDs, increasing the risk of specific adverse events:

 

AED Adverse events
Clobazam Increased incidence of somnolence and transaminase elevations
Valproate Increased incidence of transaminase elevations, diarrhoea and events of decreased appetite
Stiripentol Minor decrease in CBD active metabolite and increase in stiripentol levels. Clinical importance has not been studied. Patients should be closely monitored for adverse drug reactions.
Phenytoin Exposure to phenytoin may be increased when it is co-administered with cannabidiol. Assessed in vitro, not assessed in human clinical trials
Lamotrigine Lamotrigine levels may be elevated when it is co-administered with cannabidiol. Assessed in vitro, not assessed in human clinical trials
horizontal-header
1
bold
False

For more information about how to adjust dosage when co-administrating with other medications and recommended monitoring for patients taking Epidyolex, see dosing & monitoring.

The most common adverse events (≥10% patients) associated with Epidyolex are:1

 

  • Decreased appetite

  • Pyrexia

  • Somnolence

  • Diarrhoea

  • Vomiting

  • Fatigue

 

The most frequent cause of discontinuation was transaminase elevation.

Image
image
Sign up and stay up to date

Receive promotional communications and notifications about open-label extension data, our latest conference activity, key opinions from leading researchers and prescribers in cannabinoid therapy. 


References

 

1. Epidyolex SmPC (Date accessed: April 2021).